Does cyclooxygenase-2 affect blood pressure?

Current Hypertension Reports

Volumn 5, Issue 1, 2003, Pages 87-92

  Cheng, Hui Fang ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETODOLAC; ETORICOXIB; IBUPROFEN; INDOMETACIN; IRBESARTAN; LISINOPRIL; LOSARTAN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN E2; RENIN; ROFECOXIB; SODIUM; UNINDEXED DRUG; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN;

BLOOD PRESSURE REGULATION; BLOOD VOLUME; DISEASE EXACERBATION; DOG; DRUG ANTAGONISM; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; HYPOVOLEMIA; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; NONHUMAN; ORGAN PERFUSION; PERIPHERAL EDEMA; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; REVIEW; SODIUM EXCRETION; BLOOD PRESSURE; DRUG EFFECT; ENZYMOLOGY; KIDNEY; KIDNEY CIRCULATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; URINE;

BLOOD PRESSURE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; ISOENZYMES; KIDNEY; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RENAL CIRCULATION; RENIN-ANGIOTENSIN SYSTEM; SODIUM;

EID: 0038012992     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-003-0016-y     Document Type: Review

References (50)

1. Lipsky PE: Specific COX-2 inhibitors in arthritis, oncology, and beyond: where is the science headed? J Rheumatol 1999, 26(Suppl 56):25-30.
2. Xie WL, Chipman JG, Robertson DL, et al.: Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A 1991, 88:2692-2696.
3. Tazawa R, Xu XM, Wu KK, Wang LH: Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochem Biophys Res Commun 1994, 203:190-199.
4. Komhoff M, Grone HJ, Klein T, et al.: Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol 1997, 272:F460-F468.
5. Harris RC, McKanna JA, Akai Y, et al.: Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994, 94:2504-2510.
6. Cheng HF, Wang JL, Zhang MZ, et al.: Role of p38 in the regulation of renal cortical cyclooxygenase-2 expression by extracellular chloride. J Clin Invest 2000, 106:681-688.
7. Nantel F, Meadows E, Denis D, et al.: Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly. FEBS Lett 1999, 457:475-477.
8. Yang T, Singh I, Pham H, et al.: Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am J Physiol 1998, 274:F481-489.
9. Cheng HF, Wang JL, Zhang MZ, et al.: Angiotensin II attenuates renal cortical cyclooxygenase-2 expression. J Clin Invest 1999, 103:953-961.
10. Traynor TR, Smart A, Briggs JP, Schnermann J: Inhibition of macula densa-stimulated renin secretion by pharmacological blockade of cyclooxygenase-2. Am J Physiol 1999, 277:F706-710.
11. Kammerl MC, Nusing RM, Richthammer W, et al.: Inhibition of COX-2 counteracts the effects of diuretics in rats. Kidney Int 2001, 60:1684-1691.
12. Cheng HF, Wang JL, Zhang MZ, et al.: Genetic deletion of COX-2 prevents increased renin expression in response to ACE inhibition. Am J Physiol Renal Physiol 2001, 280:F449-456.
13. Yang T, Endo Y, Huang YG, et al.: Renin expression in COX-2-knockout mice on normal or low-salt diets. Am J Physiol Renal Physiol 2000, 279:F819-825.
14. Athirakul K, Kim HS, Audoly LP, et al.: Deficiency of COX-1 causes natriuresis and enhanced sensitivity to ACE inhibition. Kidney Int 2001, 60:2324-2329.
15. Khan KN, Stanfield KM, Harris RK, Baron DA: Expression of cyclooxygenase-2 in the macula densa of human kidney in hypertension, congestive heart failure, and diabetic nephropathy. Renal Fail 2001, 23:321-330.
16. Komhoff M, Jeck ND, Seyberth HW et al.: Cyclooxygenase-2 expression is associated with the renal macula densa of patients with Bartter-like syndrome. Kidney Int 2000, 58:2420-2424.
17. Kammerl MC, Nusing RM, Schweda F, et al.: Low sodium and furosemide-induced stimulation of the renin system in man is mediated by cyclooxygenase 2. Clin Pharmacol Ther 2001, 70:468-474.
18. Stichtenoth DO, Wagner B, Frolich JC: Effect of selective inhibition of the inducible cyclooxygenase on renin release in healthy volunteers. J Investig Med 1998, 46:290-296.
19. Reinalter SC, Jeck N, Brochhausen C, et al.: Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome. Kidney Int 2002, 62:253-260.
20. Harris RC Jr: Cyclooxygenase-2 inhibition and renal physiology. Am J Cardiol 2002, 89:10D-17D.
21. Harris RC, Breyer MD: Physiological regulation of cyclooxygenase-2 in the kidney. Am J Physiol Renal Physiol 2001, 281:F1-11.
22. Gross JM, Dwyer JE, Knox FG: Natriuretic response to increased pressure is preserved with COX-2 inhibitors. Hypertension 1999, 34:1163-1167.
23. Lopez-Parra M, Claria J, Planaguma A, et al.: Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites. Br J Pharmacol 2002, 135:891-900.
24. Vio CP, Cespedes C, Gallardo P, Masferrer JL: Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells. Hypertension 1997, 30:687-692.
25. Rodriguez F, Llinas MT, Gonzalez JD, et al.: Renal changes induced by a cyclooxygenase-2 inhibitor during normal and low sodium intake. Hypertension 2000, 36:276-281.
26. Svendsen KB, Bech JN, Sorensen TB, Pedersen EB: A comparison of the effects of etodolac and ibuprofen on renal haemodynamics, tubular function, renin, vasopressin and urinary excretion of albumin and alpha-glutathione-S-transferase in healthy subjects: a placebo-controlled cross-over study. Eur J Clin Pharmacol 2000, 56:383-388.
27. Rossat J, Maillard M, Nussberger J, et al.: Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999, 66:76-84.
28. Catella-Lawson F, McAdam B, Morrison BW, et al.: Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999, 289:735-741.
29. Whelton A, Schulman G, Wallemark C, et al.: Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000, 160:1465-1470.
30. McAdam BF, Catella-Lawson F, Mardini IA, et al.: Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999, 96:272-277.
31. Komers R, Lindsley JN, Oyama TT, et al.: Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J Clin Invest 2001, 107:889-898.
32. Kistler T, Ambuhl PM: Renal safety of combined cyclooxygenase 2 (COX-2) inhibitor and angiotensin II receptor blocker administration in mild volume depletion. Swiss Med Wkly 2001, 131:193-198.
33. Chen BH: COX-2 inhibitors and renal function in elderly people. Can Med Assoc J 2000, 163:604.
34. Swan SK, Rudy DW, Lasseter KC, et al.: Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med 2000, 133:1-9.
35. Ahmad SR, Kortepeter C, Brinker A, et al.: Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf 2002, 25:537-544.
36. Johnson AG, Nguyen TV, Day RO: Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994, 121:289-300.
37. Pope JE, Anderson JJ, Felson DT: A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993, 153:477-484.
38. Nusing RM, Reinalter SC, Peters M, et al.: Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome: therapeutic use of the cyclooxygenase-2 inhibitor nimesulide. Clin Pharmacol Ther 2001, 70:384-390.
39. Wang JL, Cheng HF, Harris RC: Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension. Hypertension 1999, 34:96-101.
40. Silverstein FE, Faich G, Goldstein JL, et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti- inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000, 284:1247-1255.
41. Brater DC, Harris C, Redfern JS, Gertz BJ: Renal effects of COX-2-selective inhibitors. Am J Nephrol 2001, 21:1-15.
42. Emery P, Zeidler H, Kvien TK, et al.: Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999, 354:2106-2111.
43. Bombardier C, Laine L, Reicin A, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000, 343:1520-1528.
44. FDA Arthritis Advisory Committee Meeting. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_01_merck.pdf. Accessed December 2001.
45. Whelton A, Maurath CJ, Verburg KM, Geis GS: Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther 2000, 7:159-175.
46. Collantes E, Curtis SP, Lee KW, et al.: A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. BMC Fam Pract 2002, 3:10.
47. White WB, Kent J, Taylor A, et al.: Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002, 39:929-934.
48. Whelton A: Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors. Am J Med 2001, 110(Suppl 3A):33S-42S.
49. Singh G, Triadafilopoulos G: Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999, 26(Suppl 56):18-24.
50. Whelton A: Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999, 106:13S-24S.